- Home
- HBT vs AMLX Comparison
HBT vs AMLX Comparison
Compare HBT & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBT
- AMLX
- Stock Information
- Founded
- HBT 1920
- AMLX 2014
- Country
- HBT United States
- AMLX United States
- Employees
- HBT N/A
- AMLX N/A
- Industry
- HBT Major Banks
- AMLX Biotechnology: Pharmaceutical Preparations
- Sector
- HBT Finance
- AMLX Health Care
- Exchange
- HBT Nasdaq
- AMLX Nasdaq
- Market Cap
- HBT 812.0M
- AMLX 684.6M
- IPO Year
- HBT 2019
- AMLX 2022
- Fundamental
- Price
- HBT $24.03
- AMLX $7.72
- Analyst Decision
- HBT Hold
- AMLX Strong Buy
- Analyst Count
- HBT 6
- AMLX 7
- Target Price
- HBT $28.00
- AMLX $12.00
- AVG Volume (30 Days)
- HBT 28.6K
- AMLX 1.5M
- Earning Date
- HBT 07-21-2025
- AMLX 08-07-2025
- Dividend Yield
- HBT 3.49%
- AMLX N/A
- EPS Growth
- HBT 8.10
- AMLX N/A
- EPS
- HBT 2.42
- AMLX N/A
- Revenue
- HBT $229,851,000.00
- AMLX N/A
- Revenue This Year
- HBT $8.74
- AMLX N/A
- Revenue Next Year
- HBT $2.25
- AMLX N/A
- P/E Ratio
- HBT $9.94
- AMLX N/A
- Revenue Growth
- HBT 4.61
- AMLX N/A
- 52 Week Low
- HBT $19.46
- AMLX $1.76
- 52 Week High
- HBT $26.86
- AMLX $8.72
- Technical
- Relative Strength Index (RSI)
- HBT 37.33
- AMLX 54.70
- Support Level
- HBT $25.27
- AMLX $7.84
- Resistance Level
- HBT $26.00
- AMLX $8.29
- Average True Range (ATR)
- HBT 0.79
- AMLX 0.45
- MACD
- HBT -0.25
- AMLX -0.13
- Stochastic Oscillator
- HBT 1.05
- AMLX 2.90
About HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.